"us-food-and-drug-administration-us-fda"

It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nexium Delayed-Release Capsules, 20 mg and 40 mg, of AstraZeneca Pharmaceuticals LP.

Neuralink said in a tweet, "This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," it added.

Even a single dose of the mRNA vaccines can reduce the risk of infection by 81 per cent. These estimates included symptomatic and asymptomatic infections.

Advent announced that it has signed a definitive agreement to acquire a controlling stake in ZCL Chemicals